Комплексный подход к лечению эректильной дисфункции у больных c ожирением и метаболическим синдромом
Комплексный подход к лечению эректильной дисфункции у больных c ожирением и метаболическим синдромом
Роживанов Р.В., Тишова Ю.А., Шурдумова Б.О., Савельева Л.В. Комплексный подход к лечению эректильной дисфункции у больных c ожирением и метаболическим синдромом. Consilium Medicum. 2009; 11 (12): 67–70.
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Список литературы
- Андрология. Мужское здоровье и дисфункция репродуктивной системы. Под ред. Э.Нишлага, Г.М.Бере. М., 2005.
- Бутрова С.А. Лечение ожирения. Материалы 1-го Московского съезда эндокринологов. Современные концепции клинической эндокринологии. М., 1997; с. 172–7.
- Григорьев П.Я., Исаков В.А., Яковенко Э.П. Патогенетические основы алиментарного ожирения. Тер. арх. 1989; 61 (9): 120–5.
- Ивлева А.Я., Старостина Е.Г. Ожирение – проблема медицинская, а не косметическая. М.: 2002; с. 22.
- Калинченко С.Ю. Ожирение и нарушения репродуктивной функции у мужчин. В кн.: Ожирение. Под ред. И.И.Дедова, Г.А.Мельниченко. М., 2004; с. 185–216.
- Нарушения половой функции у мужчин при сахарном диабете. Под ред. М.И.Коган. М., 2005.
- Рафальский В.В. Подходы к рациональному выбору ингибиторов фосфодиэстеразы 5 типа. Фарматека. 2004; 19 (20): 1–8.
- Татонь Я. Ожирение: патофизиология, диагностика, лечение. М.: Медицина, 1981.
- Угланова Т.М. Патогенез, классификация и терапия ожирения. Сб. научн. трудов. Патология метаболизма: атеросклероз, ожирение, сахарный диабет. Н. Новгород, 1992; с. 83–91.
- American Diabetes Association. Management of Dyslipidemia in Adults With Diabetes. Position Statement. J Diabetes Care 1999; 22: 9–56.
- Anderson К.A., Costelli W.R., Levy D. J Am Med Assoc 1987; 257: 2176–80.
- Armellini et al. Hormones and body composition in humans: clinical studies. Int J Obes Relat Metab Disord 2000; 24 (Suppl. 2): S18–21.
- Bansal T.C., Guay A., Jacobson J et al. Incidence of metabolic syndrome and insulin resistance in a population with organic erectile dysfunction. J Sex Med 2005; 2: 96–103.
- Bjorntorp P. Visceral fat accumulation: the missing link between psychosocial factors and cardiovascular disease? J Intern Med 1991; 230: 195–201.
- Bray G.A. Contemporary diagnosis and management of obesity. Newton.: Handbooks in Health Care CO, 2000.
- Brock G. Oral agents: First - line therapy for erectile dysfunction. Eur Urol 2002; suppl. 1: 12–8.
- Cunningham G.R. Management of male aging: which testosterone replacement therapy should be used? The Aging Male 2000; 3: 203–9.
- Dobs et al. Interrelationships among lipoprotein levels, sex hormones, anthropometric parameters, and age in hypogonadal men treated for 1 year with a permeation - enhanced testosterone transdermal system. J Clin Endocrinol Metab 2001; 86 (3): 1026–33.
- Esposito K, Giugliano F, Di Palo C et al. Effect of lifestyle changes on erectile dysfunction in obese men: a randomized controlled trial. JAMA 2004; 291 (24): 2978–84.
- Esposito К, Giugliano D Obesity, the metabolic syndrome, and sexual dysfunction. Int J Impot Res 2005; 17: 391–8.
- Goldstein I, Young J.M., Fisher I et al. Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: a multicenter, double - blind, placebo - controlled, fixed - dose study. Diabetes Care 2003; 26: 777–83.
- Grundy S.M. Multifactorial causation of obesity: implications for prevention. Am J Clin Nutr 1998; 67 (Suppl. 1): 563S–72S.
- Hak et al. Тhe Rotterdam study, Low levels of endogenous androgens increase the risk of atherosclerosis in elderly men: the Rotterdam study. J Clin Endocrinol Metab 2002; 87 (8): 3632–9.
- Haffner S.M., Miettinen H, Mykkanen L, Stern M.P. Leptin concentrations are associated with higher proinsulin and insulin concentrations but a lower proinsulin/insulin ratio in non - diabetic subjects. Int J Obes Relat Metab Disord 1998; 22 (9): 899–905.
- Hellstrom W.J.G., Gittelman M, Karlin G et al. Vardenafll for treatment of men with erectile dysfunction: Efficacy and safety in a randomised, double - blind, placebo - controlled trial. J Androl 2002; 23: 763–71.
- Hellstrom W, Gittelman M, Karlin G et al. Sustained efficacy and tolerability of vardenafil (LevitraR), a highly potent, selective phosphodiesterase - 5 inhibitor, in men with erectile dysfunction: results of a randomised, double - blind, 26 - week placebo - controlled pivotal trial. Urology 2003; 26: 777–83.
- Hu G, Qiao Q, Tuomilehto J et al.; DECODE Study Group. Prevalence of the metabolic syndrome and its relation to all - cause and cardiovascular mortality in nondiabetic European men and women. Arch Intern Med 2004; 164 (10): 1066–76.
- Isomaa B, Almgren P, Tuomi T et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24 (4): 683–9.
- ISA, ISSAM, EAU, EAA and ASA Recommendations: Investigation, Treatment and Monitoring of Late - Onset Hypogonadism in Males. Sept. 2008, The Aging Male.
- Katznelson et al. Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. J Clin Endocrinol Metab 1996; 81 (12): 4358–65.
- Kendall D.M., Sobel B.E., Coulston A.M. The insulin resistance syndrome and coronary artery disease. Coron Artery Dis 2003; 14 (4): 335–48.
- Khaw K.T., Barrett-Connor E. Lower endogenous androgens predict central adiposity in men. Ann Epidemiol 1992; 2 (5): 675–82.
- Kissebah A.H., Evans D.J., Peiris A, Wilson C.R. Endocrine characteristics in regional obesities role of sex steroids. Excerpta Medica. Amsterdam 1985; p. 115–30.
- Kissebah A.H., Krakower G.R. Regional adiposity and morbidity. Physiol Rev 1994; 74: 761–811.
- Laaksoner D.E., Lokka H.M. et al. Am J Epidemiol 2002; 156: 1070–7.
- Laaksonen et al. Sex hormones, inflammation and the metabolic syndrome: a population - based study. Eur J Endocrinol 2003; 149 (6): 601–8.
- Leenen R, van der Kooy K, Seidell J.C. et al. Visceral fat accumulation in relation to sex hormones in obese men and women undergoing weight loss therapy. J Clin Endocrinol Metab 1994; 78: 1515–20.
- Levine A.S., Giraudo S.Q., Kotz С.М., Billington C.J. Neuropeptides: regulators of energy -, stressand «reward» - induced feeding. Int J Obes 2000; 24 (Suppl. l): S6.
- Marin P, Holmang S, Jonsson L et al. The effects of testosterone treatment on body composition and metabolism in middle - aged obese men. Int J Obesity 1992; 16: 991–7.
- Marin P, Arver S. Androgens and abdominal obesity. Baillieres Clin Endocrinol Metab 1998; 12 (3): 441–51.
- Pasquali R, Casimirri F, De Iasio R et al. Insulin regulates testosterone and sex hormone - binding globulin concentrations in adult normal weight and obese men. J Clin Endocrinol Metab 1995; 80: 654–8.
- Phillips G.B., Pinkernell B.H., Jing T.Y. The association of hypotestosteronemia with coronary artery disease in men. Arterioscler Thromb 1994; 14 (5): 701–6.
- Roncavi D.A.K., Van R.L.R. Promotion of human adipocite precursor replication by 17 b - estradiol in culture. J Clin Invest 1977; 62: 503–8.
- Rubio-Aurioles E, Porst H, Eardley I, Goldstein I and Vardenafil - Sildenafil Comparator Study Group. Comparing vardenafil and sildenafil in the treatment of men with erectile dysfunction and risk factors for cardiovascular disease: a randomized, double - blind, pooled crossover study. J Sex Med 2006; 3 (6): 1037–49.
- Sachse R, Rohde G, Stark S, Klotz T. Safety, tolerability and pharmacokinetics of BAY 38-9456 in patients with erectile dysfunction. J Urol (Baltimore) 2000; Suppl.: abstr. 2693.
- Seidell J.C., Bjorntorp P, Sjostrom L et al. Visceral fat accumulation in men is positively associated with insulin, glucose, and C-peptide levels, but negatively with testosterone levels. Metabolism 1990; 39 (9): 897–901.
- Simon et al. Association between plasma total testosterone and cardiovascular risk factors in healthy adult men: The Telecom Study. J Clin Endocrinol Metab 1997; 82 (2): 682–5.
- Stellato R.K., Feldman H.A., Hamdy O et al. Testosterone, sex hormone - binding globulin, and the development of type 2 diabetes in middle - aged men: prospective results from the Massachusetts male aging study. Diabetes Care 2000; 23 (4): 490–4.
- Svartberg J et al. Waist circumference and testosterone levels in community dwelling men. The Tromsњ study. Eur J Epidemiol 2004; 19 (7): 657–63.
- Tsai E.C., Boyko E.J., Leonetti D.L., Fujimoto W.Y. Low serum testosterone level as predictor of increased visceral fat in Japanese - American men. Int J Obes Relat Metab Disord 2000; 24: 485–91.
- Wang C et al. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. J Clin Endocrinol Metab 2000; 85 (8): 2839–53.
Авторы
Роживанов Р.В., Тишова Ю.А., Шурдумова Б.О., Савельева Л.В.
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.